CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cidara Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cidara Therapeutics Inc
6310 Nancy Ridge Dr Ste 101
Phone: (858) 752-6170p:858 752-6170 SAN DIEGO, CA  92121-3209  United States Ticker: CDTXCDTX

Business Summary
Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Principal Financial Officer, Director Jeffrey L.Stein 64 8/17/2018 1/1/2014
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer James E.Levine 44 12/3/2018 12/3/2018
Chief Operating Officer PaulDaruwala 47 1/1/2017 12/1/2014
10 additional Officers and Directors records available in full report.

Business Names
Business Name
CDTX
Cidara Therapeutics (Ireland) Limited
Cidara Therapeutics UK Limited

General Information
Number of Employees: 68 (As of 2/15/2019)
Outstanding Shares: 33,040,295 (As of 10/31/2019)
Shareholders: 26
Stock Exchange: NASD
Federal Tax Id: 461537286
Fax Number: (302) 655-5049


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, November 19, 2019